[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Uzbekistan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":580},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,56,86,122,155,189,217,251,274,300,328,345,365,394,416,440,466,495,526,556],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100629557","predictors-of-androgen-status-decline-in-middle-aged-men-100629557",false,"NCT07476222","Anthropometric, Functional and Lifestyle Factors Associated With Testosterone Levels in Middle-Aged Men","Anthropometric, Functional and Lifestyle-related Factors Associated With Testosterone Levels Among Middle-aged Men in Uzbekistan: Protocol for a Population-based Cross-sectional Study","TESMEN","Inclusion Criteria:\n\n* Men aged 35-59 years\n* Permanent residence in the Andijan region of Uzbekistan\n* Ability and willingness to provide written informed consent\n* Willingness to undergo clinical, anthropometric, functional and laboratory assessments\n\nExclusion Criteria:\n\n* Previously diagnosed hypogonadism requiring testosterone replacement therapy\n* Current use of testosterone preparations or other medications known to substantially affect androgen status\n* Severe cardiovascular, hepatic or renal disease in the stage of decompensation\n* Clinically significant urological pathology\n* Severe psychiatric illness or cognitive impairment limiting study participation\n* Acute infectious or inflammatory conditions at the time of assessment",true,"MALE","35 Years","59 Years",{"count":22,"type":23},600,"ESTIMATED","OBSERVATIONAL","Decreased testosterone levels in middle-aged men are associated with multiple metabolic, functional and psychosocial consequences. Early identification of modifiable factors associated with reduced testosterone levels may facilitate the early identification of men at increased risk of testosterone deficiency and support preventive healthcare strategies.\n\nThis population-based cross-sectional observational study aims to investigate anthropometric, functional and lifestyle-related factors associated with serum total testosterone levels in middle-aged men. Approximately 600 men aged 35-59 years residing in the Andijan region of Uzbekistan will be recruited.\n\nParticipants will undergo comprehensive assessment including anthropometric measurements, functional performance tests, standardised questionnaires and laboratory determination of serum total testosterone concentrations. Anthropometric variables will include body mass index, waist circumference, hip circumference, waist-to-hip ratio and waist-to-height ratio. Functional status will be assessed using hand-grip strength, the five-times chair-stand test and the 4-m walk test. Lifestyle-related factors will be assessed using standardised and study-specific questionnaires. Physical activity will be assessed using the International Physical Activity Questionnaire-Short Form (IPAQ-SF), while dietary habits, sleep characteristics, smoking status, alcohol consumption and psychosocial characteristics will be assessed using a structured study questionnaire.\n\nThe study aims to identify factors associated with serum total testosterone levels and to develop a predictive model for the early identification of men at increased risk of testosterone deficiency.",[27,28],"Testosterone Deficiency","Male Hypogonadism",[30,31,32,33,34,35,36,37,38,39,40,41,42],"Testosterone deficiency","Cross-sectional study","Men's health","Sarcopenia","Waist circumference","Body mass index","Sleep quality","Physical activity","Lifestyle factors","Functional status","Anthropometric factors","Middle-aged men","Screening model","RECRUITING","2026-08-22",{"date":46,"type":47},"2026-08-25","ACTUAL",{"date":49,"type":47},"2026-06-01",{"date":51,"type":23},"2027-12-31",{"name":53,"class":54},"Andijan State Medical Institute","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100608388","phase-3-a-trial-evaluating-brelovitug-bjt-778-vs-bulevirtide-for-the-treatment-of-chronic-hepatitis-delta-infection-azure-2-100608388","NCT07200908","A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)","A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)","Key Inclusion Criteria:\n\n1. Willing and able to provide written informed consent\n2. Chronic HDV infection\n3. HDV RNA \\>500 IU\u002FmL at Screening\n4. ALT \\>ULN at Screening\n5. Willing to take or already taking HBV neucleos(t)ide therapy.\n\nKey Exclusion Criteria:\n\n1. Pregnant or nursing females\n2. Unwilling to comply with contraception requirements during the study\n3. Difficulty with blood collection and\u002For poor venous access for the purposes of phlebotomy\n4. Clinical hepatic decompensation (i.e., ascites, encephalopathy variceal hemorrhage).\n5. Solid organ or bone marrow transplantation\n6. Presence of other liver disease(s) (non-HBV\u002FHDV), such as nonalcoholic steatohepatitis (NASH), alcohol associated hepatitis, cholestatic liver disease, hepatocellular carcinoma.\n\nNote - Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years","99 Years",{"count":67,"type":23},172,"INTERVENTIONAL",[70],"PHASE3","This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD). The main goal of this study is to test the effectiveness of brelovitug compared to bulevirtide as a long-term treatment in patients with chronic HDV infection.",[73],"Chronic Hepatitis D Infection",[75],"Hepatitis Delta virus, HDV, Hepatitis D infection; Hepatitis D virus","2026-08-21",{"date":46,"type":47},{"date":79,"type":47},"2025-08-27",{"date":81,"type":23},"2029-09-30",{"name":83,"class":84},"Mirum Pharmaceuticals, Inc.","INDUSTRY",53,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":68,"phases":95,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100633242","phase-1-a-first-in-human-study-of-ze94-0605-in-patients-with-advanced-solid-tumors-100633242","NCT07524140","A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors","A Phase 1, First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\nPhase 1a Dose-Escalation Cohorts:\n\n1. Age 18 years or older with a pathologically confirmed, advanced, unresectable or metastatic solid tumor that is refractory to, or intolerant of, available existing therapy or therapies known to provide clinical benefit for the condition, if available, and with measurable disease.\n\n   Phase 1b Dose-Expansion Cohorts:\n2. Age 18 years or older with a pathologically confirmed, advanced, unresectable or metastatic solid tumor that is refractory to, or intolerant of, available existing therapy or therapies known to provide clinical benefit for the condition, if available, or who has declined such therapy; presence of CCNE1 amplification; and measurable disease.\n\n   Common Eligibility Criteria:\n3. Eastern Cooperative Oncology Group performance status of 0 or 1.\n4. Adequate end-organ function, defined as creatinine clearance greater than 60 mL\u002Fmin, aspartate aminotransferase and alanine aminotransferase less than 3 times the upper limit of normal, and total bilirubin less than 1.5 times the upper limit of normal, except for participants with Gilbert's disease.\n5. Absolute neutrophil count at least 1.5 × 10\\^9\u002FL and platelet count at least 100 × 10\\^9\u002FL.\n6. Female participants of childbearing potential must be willing to abstain from heterosexual intercourse or use a protocol-recommended method of contraception from screening throughout study treatment and for 90 days after the last dose of ZE94-0605.\n7. Male participants of reproductive potential who have intercourse with females of childbearing potential must be willing to abstain from heterosexual intercourse or use a protocol-recommended method of contraception from the start of study treatment throughout study treatment and for 90 days after the last dose of ZE94-0605. Male participants must also refrain from sperm donation during this period.\n8. Willingness to comply with scheduled visits, the drug-administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions.\n\nExclusion Criteria:\n\n1. History of another malignancy, except adequately treated local basal cell carcinoma or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease, or another cancer that has been in complete remission without treatment for at least 2 years before enrollment or has a life expectancy of 24 months and does not require therapy that would confound interpretation of this study. Such cases must be discussed with the Medical Monitor before screening.\n2. Known active hepatitis C, hepatitis B, or human immunodeficiency virus infection.\n3. Pregnancy or breastfeeding.\n4. Concurrent participation in an investigational-drug trial with therapeutic intent, defined as receipt of prior study therapy within 14 days before study treatment.\n5. Inability to tolerate oral medication, including symptomatic disease that significantly affects gastrointestinal function, such as inflammatory bowel disease or resection of the stomach or small bowel.\n6. Receipt of an investigational agent for any indication within 5 half-lives of the agent. If the half-life is unknown, the participant must wait 1 week before the first dose of study treatment. An investigational agent is one for which there is no approved indication from the U.S. Food and Drug Administration.\n7. Psychological, familial, social, or geographic factors; another significant medical condition; or a laboratory abnormality that precludes informed consent or protocol compliance, may hamper adherence to study treatment or follow-up, or would confound interpretation of study results.\n8. Uncontrolled intercurrent illness, including but not limited to symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, New York Heart Association Class III or IV heart failure, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction-system abnormalities. Participants with medical comorbidities that would preclude safety evaluation of ZE94-0605 must not be enrolled.\n9. QT interval corrected using Fridericia's formula (QTcF) greater than or equal to 470 milliseconds, unless the participant has a pacemaker. Participants with an incomplete or complete right or left bundle branch block may participate if cleared for enrollment by a cardiology evaluation.",{"count":94,"type":23},60,[96],"PHASE1","ZE94-0605 is an oral, selective cyclin-dependent kinase 2 (CDK2) inhibitor. This multicenter, open-label, first-in-human Phase 1 study will evaluate ZE94-0605 in adults with advanced, unresectable or metastatic solid tumors. Phase 1a will use sequential dose escalation to determine the maximally tolerated dose and biologically effective dose. Phase 1b will randomize participants with CCNE1 amplification, or another prospectively specified molecular feature, between two dose levels to select the recommended Phase 2 dose.",[99,100],"Advanced Solid Tumor Cancer","Metastatic Solid Tumor",[102,103,104,105,106,107,108,109,110,111],"ZE94-0605","Selective CDK2 inhibitor","CCNE1 amplification","Cyclin E1","First-in-human","Dose escalation","Dose optimization","Recommended Phase 2 dose","Project Optimus","Brain-penetrant CDK2 inhibitor","2026-07-28",{"date":114,"type":47},"2026-07-29",{"date":116,"type":47},"2026-06-25",{"date":118,"type":23},"2028-05",{"name":120,"class":84},"Eilean Therapeutics",3,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":63,"minAge":129,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":68,"phases":132,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100478314","lumbar-operatively-inserted-perqdisc-artificial-implant-following-nulcectomy-lopain2-100478314","NCT05508360","\"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy\" (LOPAIN2)","LOPAIN2","Inclusion Criteria:\n\n* Patient is skeletally mature aged 22-70.\n* Patient has Degenerative Disc Disease (DDD) at one or more levels between L1 and S1 but the discogenic pain must be limited to a single level.\n* Patient has adequate disc height (6mm) at the level to be treated\n* Patient has exhausted a minimum of 6 months of conservative treatment for their back (e.g. physical therapy, medications, injections, life style changes, etc).\n* Patient has a preoperative Oswestry Disability questionnaire score ≥ 40 out of 100 points (40\u002F100)\n* Patient has a low back pain Visual Analog Scale (VAS) ≥ 40 mm (4 cm)\n* Patient has signed the approved Informed Consent Form.\n* All surgeries must be approved by the Medical Advisory Board (MAB)\n\nExclusion Criteria:\n\n* Patient has less than 6 mm of disc height.\n* Patient has had prior lumbar spine surgery (nucleoplasty at non-index level is considered acceptable).\n* Patient has had spinal fusion in the lumbar or thoracic intervertebral spaces. Cervical fusion is allowed as long as there are no neurologic deficits in the lower extremities.\n* Patient has spondyloarthropathy or other spondylolisthesis greater than 2 mm.\n* Patient has congenital moderate or severe spinal stenosis or epidural lipomatosis.\n* Patient has significant facet disease. Significant is defined as pain improvement of 80% or more following image-guided medial branch blocks of the target level according to SIS guidelines (diagnostic, contrast controlled).\n* Patient has any known active malignancy.\n* Patient has previously undergone or currently on immunosuppressive therapy. Steroids used to treat inflammation are allowed.\n* Patient has active or local systemic infection.\n* Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus, or other autoimmune disease including AIDS, ARC and HIV.\n* Patient has diabetes mellitus (Type 1 or 2) requiring daily insulin management.\n* Patient has osteopenia of the spine (T-score of -1.0 or lower). A DEXA scan should be performed to rule out patients considered at risk for osteopenia.\n* Patient has morbid obesity defined as a body mass index (BMI) more than 40 or a weight of more than 45 kg (100 lbs.) over ideal body weight.\n* Patient has a known allergy to silicone or barium sulfate.\n* Patient has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.\n* Patient has a significant Schmorl's node in the level to be treated. Significant is defined as a large, rectangular or irregular shaped node that has an associated active inflammatory process (Modic I changes).\n* Patient has motion of less than 3 degrees on pre-operative lateral flexion\u002Fextension radiographs.\n* Patient belongs to a vulnerable population or has a condition such that his\u002Fher ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally, disabled, prisoner, chronic alcohol\u002F substance abuser)\n\nIntraoperative Exclusion Criteria:\n\n* Protrusion of the 20A Imaging Balloon up to or beyond the outer margin of the vertebra during the imaging steps.\n* Patient has a violated endplate as determined by imaging balloons during fluoroscopy.\n* Patient has a disc space that is too narrow for implantation. MIPL Specific\n* Poor radiological visualization of Kambin's triangle.\n* Sustained irritation of the exiting nerve root during any aspect of the annular dilation technique (leg movement or if performing with electrical monitoring) in spite or repositioning instruments.","22 Years",{"count":131,"type":23},72,[133],"NA","This study will be a prospective, open-label, multi-center study including 72 patients that will collect additional safety and efficacy data for the Spinal Stabilization Technologies PerQdisc Nucleus Replacement System.",[136,137],"Degenerative Disc Disease","Chronic Low-back Pain",[136,139,140,141,142,143,144],"DDD","Chronic Low Back Pain","cLBP","Disc Herniation","Nucleus Replacement","Low Back Pain","2026-07-24",{"date":147,"type":47},"2026-07-27",{"date":149,"type":47},"2022-08-22",{"date":151,"type":23},"2030-08-22",{"name":153,"class":84},"Spinal Stabilization Technologies",11,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":55},"100647448","internal-organ-and-musculoskeletal-assessment-in-hypothyroidism-hypomorph-100647448","NCT07707830","Internal Organ and Musculoskeletal Assessment in Hypothyroidism (HYPOMORPH)","Morphometric Characteristics of Internal Organs and Morphofunctional Status of the Musculoskeletal System in Patients With Hypothyroidism","HYPOMORPH","Inclusion Criteria:\n\n* Adults aged 18-59 years.\n* Previously established diagnosis of hypothyroidism.\n* Receiving routine outpatient or inpatient care at participating healthcare institutions.\n* Ability to undergo ultrasonographic, anthropometric, and functional assessments.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* History of thyroid malignancy.\n* Acute infectious or inflammatory disease at the time of enrollment.\n* Severe decompensated cardiovascular, hepatic, or renal disease preventing study procedures.\n* Neurological or musculoskeletal disorders that preclude functional testing.\n* Refusal or inability to provide informed consent.\n* Incomplete clinical or laboratory data.",{"count":164,"type":23},500,"This hospital-based observational cross-sectional study aims to investigate the morphometric characteristics of internal organs and the morphofunctional status of the musculoskeletal system in adult patients with previously diagnosed hypothyroidism. The study will evaluate ultrasonographic morphometric characteristics of the liver, pancreas, and kidneys, as well as anthropometric and functional characteristics of the musculoskeletal system. Associations between these outcomes and clinical characteristics, anthropometric parameters, physical activity, and laboratory findings will also be assessed. The study is expected to identify accessible clinical, anthropometric, and functional markers associated with morphometric and musculoskeletal changes in patients with hypothyroidism, thereby improving risk assessment and early detection of systemic involvement.",[167],"Hypothyroidism",[167,169,170,171,172,173,174,175,176,177,178,179],"Ultrasonography","Morphometry","Liver","Pancreas","Kidney","Musculoskeletal System","Anthropometry","Physical Function","Cross-Sectional Study","Physical Activity","Physical Inactivity","NOT_YET_RECRUITING","2026-07-14",{"date":183,"type":47},"2026-07-16",{"date":185,"type":23},"2026-08-01",{"date":187,"type":23},"2028-12-31",{"name":53,"class":54},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":68,"phases":199,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":121},"100546993","coloseal-icd-system-safety-and-feasibility-study-100546993","NCT06402188","ColoSeal™ ICD System Safety and Feasibility Study","European ColoSeal™ ICD System Safety and Feasibility Study","Inclusion Criteria:\n\n* Subject is 18-65 years of age at screening, or subject is 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed.\n* Subject is diagnosed with rectosigmoid or rectal cancer\n* Subject is scheduled for elective resection, either open, laparoscopic or robotic with mesorectal excision (either abdominal or transanal approach) which will require the creation of an anastomosis and protective ostomy (anastomosis maximally 15 cm from the anal verge).\n* The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB).\n* Subject must be willing and able to comply with study follow-up requirements.\n\nExclusion Criteria:\n\n* Subject with a life expectancy \\\u003C 1 year\n* Subjects with ASA classification \\> 3\n* Albumin \\\u003C 30 g\u002Fliter\n* Subject has local or systemic infection at the time of intervention.\n* Major surgical or interventional procedures within 30 days prior to this study or planned major surgical or interventional procedures within 1 month of entry into this study\n* Patient has received systemic chemotherapy or radiation to the pelvis within 30 days prior to the planned procedure\n* Subject has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis, diverticulitis, or extensively spread inflammatory bowel disease\n* Subject has an anatomic abnormality (e.g., polyp, diverticula, vascular malformation) or bowel damage at or within 5 cm of the target device anchor site that could interfere with safe device function\n* Subjects has a diagnosis of coagulopathy, thrombocytopenia, immune suppression\n* BMI ≥ 40\n* Subject is scheduled for a concurrent major surgical procedure during the surgery (e.g., liver resection)\n* Subject has been taking regular systemic\u002F steroid medication in the last 3 months\n* Subjects is taking antimetabolites or antiplatelet agents (with the exception of aspirin)\n* Subject has undergone a prior pelvic anastomosis\n* Subject requires an end-to-end anastomosis smaller than 31 mm in diameter\n* Inadequate bowel preparation prior to the procedure\n* Anastomotic leak detected during intraoperative leak testing\n* Known allergy to any component of the device\n* Known allergy to iodine or iodine-based contrast unless subject can be adequately premedicated prior to leak test\n* Subject has unresolved alcohol abuse or illegal drug use\n* Any condition or abnormality which in the opinion of the investigator may jeopardize the subject's safe participation or the quality of the data\n* Subject is pregnant or planning to become pregnant. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure\n* Subject is unable or unwilling to provide informed consent\n* Subject is currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints","70 Years",{"count":198,"type":23},90,[133],"The purpose of this clinical investigation is to evaluate the safety and feasibility of the ColoSeal ICD System in a prospective, multicenter, single-arm study. The ColoSeal ICD System is intended to be used to protect a damaged segment of colon such as a surgical anastomosis, anastomosis leak, or perforation from contact with fecal flow for up to 14 days. The device will be evaluated in adult patients with rectal and rectosigmoid cancer undergoing a resection with a colorectal anastomosis.",[202],"Colorectal Cancer",[204,205,206,207],"Colon anastomosis","Rectosigmoid cancer resection","Ostomy","Colon diversion","2026-06-19",{"date":210,"type":47},"2026-06-23",{"date":212,"type":47},"2023-06-05",{"date":214,"type":23},"2026-12-31",{"name":216,"class":84},"Averto Medical, Inc.",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":18,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":68,"phases":229,"briefSummary":230,"conditions":231,"keywords":234,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":250},"100617527","fibrin-enhanced-tip-versus-grafted-tip-urethroplasty-in-distal-hypospadias-100617527","NCT07319780","Fibrin-Enhanced TIP Versus Grafted TIP Urethroplasty in Distal Hypospadias","A Multicenter Randomized Controlled Trial Comparing Fibrin-Enhanced Tubularized Incised Plate (F-TIP) and Grafted Tubularized Incised Plate (G-TIP) Urethroplasty in Distal Hypospadias With Unfavorable Urethral Plates","FTIP-RCT","Inclusion Criteria:\n\n* Male children aged 6 months to 84 months\n* Primary or redo distal hypospadias\n* Unfavorable urethral plate\n* Penile curvature less than 45 degrees after degloving\n* Eligibility for tubularized incised plate urethroplasty\n\nExclusion Criteria:\n\n* Disorders of sex development or ambiguous genitalia\n* Severe penile curvature requiring urethral plate transection\n* Previous graft-based urethroplasty\n* Active local or systemic infection at the time of surgery\n* Known bleeding or platelet disorders\n* Inability to comply with postoperative follow-up","6 Months","84 Months",{"count":228,"type":23},100,[133],"Hypospadias is a common congenital condition in boys in which the opening of the urethra is located on the underside of the penis. Distal hypospadias is the most common form and is usually treated surgically using tubularized incised plate (TIP) urethroplasty. In boys with an unfavorable urethral plate, graft-augmented techniques (G-TIP) are often used; however, postoperative complications such as urethrocutaneous fistula and narrowing of the urethral opening (meatal stenosis) may still occur.\n\nPlatelet-rich fibrin (PRF) is a biological material obtained from the patient's own blood that contains natural growth factors and may help improve tissue healing. This study aims to evaluate whether the use of PRF during surgery can reduce postoperative complications and improve surgical outcomes in children undergoing hypospadias repair.",[232,233],"Distal Hypospadias","Hypospadias",[235,236,237,238,239,240],"Hypospadias repair","Tubularized incised plate","Platelet-rich fibrin","PRF","Grafted TIP","Pediatric urology","2026-01-28",{"date":243,"type":47},"2026-01-30",{"date":245,"type":47},"2026-01-05",{"date":247,"type":23},"2028-12-25",{"name":249,"class":54},"National Children's Medical Center, Uzbekistan",2,{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":68,"phases":259,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":273},"100605014","phase-2-early-stage-trial-to-determine-a-safe-and-effective-dose-for-ratutrelvir-in-patients-with-mild-to-moderate-covid-19-100605014","NCT07157007","Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19","A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19","Inclusion Criteria:\n\n1. Confirmed SARS-CoV-2 infection for 120 h prior to randomization.\n2. Initial onset of signs\u002Fsymptoms attributable to COVID-19 within 5 days prior to randomization.\n3. At least one of the symptoms attributable to COVID-19 present within 24 hours prior to the Day 1 with the severity score of 1 or higher according to the following scoring system for the assessment of severity of:\n\nExclusion Criteria:\n\nMedical Conditions:\n\n1. History, current need for hospitalization or anticipated need for hospitalization for the medical treatment of COVID-19.\n2. Urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or ECMO.\n3. Known medical history of active liver disease .\n4. Receiving dialysis or history of moderate to severe renal impairment.\n5. Compromised immune system.\n6. Acute episode of chronic respiratory diseases, including bronchial asthma, chronic obstructive pulmonary disease within 30 days before screening.\n7. Suspected or confirmed concurrent active systemic infection..\n\n   Prior\u002FConcomitant Therapy:\n8. Has received or is expected to receive any dose of a SARS-CoV-2 vaccine within 4 months of screening and during the participation in the study.\n9. Concomitant use of any medications or substances that are strong inducers of CYP3A4",{"count":198,"type":23},[260],"PHASE2","This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.",[263],"COVID - 19","2026-01-17",{"date":266,"type":47},"2026-01-21",{"date":268,"type":47},"2025-09-16",{"date":270,"type":23},"2026-03",{"name":272,"class":84},"Traws Pharma, Inc.",15,{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":68,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":55},"100618371","first-in-human-trial-of-the-a3-shield-system-for-stabilizing-abdominal-aortic-aneurysms-100618371","NCT07330752","First-in-Human Trial of the A3-Shield System for Stabilizing Abdominal Aortic Aneurysms","PRemarket INvestigation to Evaluate the Clinical Safety and effectIveness of the Protective \"A3- Shield\" System for the stabIlIzation of Abdominal Aortic aneurysmS - Pilot Phase","PRINCIPIIS-FIH","Inclusion Criteria:\n\nIC1. Male and female subjects ≥ 18 years at the time of screening. Female subjects must be of non-childbearing potential or otherwise not pregnant and not planning to become pregnant during the study follow-up period.\n\nIC2. Subject has a documented fusiform infrarenal abdominal aortic aneurysm characterized by the following:\n\n* Aneurysm size of 3.0-5.0 cm in maximum diameter for males; 3.0 - 4.5 for females (diameter measured in CTA perpendicular to the line of flow)\n* Aortic neck diameter ≥17mm and ≤ 29mm\n* Adequate landing zone for a tubular device of ≥ 30 mm length\n\nIC3. Access vessel size and morphology allows endovascular access of 14F (or larger) introducer sheaths and catheters\n\nIC4. Subject (or legal representative) understands the study requirements and the procedures and provided written informed consent.\n\nIC5. Subject, family member, and\u002For legal representative agree(s) and subject is capable of returning to the study hospital for all required scheduled follow-up visits.\n\nExclusion Criteria:\n\nEC1. Subject has an aneurysm that is:\n\n* symptomatic\n* ruptured\n* thoracic\n* suprarenal\n* thoraco-abdominal\n* isolated ilio-femoral\n* mycotic\n* inflammatory\n* pseudoaneurysmatic\n* traumatic\n\nEC2. Subject has any type of aortic dissection.\n\nEC3. Subject has congenital connective tissue disease, e.g., Marfan's Syndrome or Ehlers-Danlos Syndrome.\n\nEC4. Subject has significant (\\>25% of vessel circumference of aortic neck) aortic mural thrombus at the attachment site that could compromise fixation of the device.\n\nEC5. Subject has arterial access that is not acceptable for the device delivery systems as defined in the device Instructions For Use.\n\nEC6. Subject has had an acute myocardial infarction within 180 days prior to the index procedure (defined as Q-wave MI or non-Q-wave MI with total CK elevation ≥ twice normal in the presence of CK-MB elevation and\u002For troponin elevation).\n\nEC7. Subject has untreated coronary artery disease, which in the opinion of the treating physician, is clinically significant and requires revascularization.\n\nEC8. Subject has congestive heart failure (NYHA class III or IV) or high-grade valvular disease.\n\nEC9. Subject has had a cerebrovascular accident or transient ischemic attack within the past 90 days prior to study enrollment.\n\nEC10. Subject has end-stage renal disease or has a creatinine \\> 2.0 mg\u002Fdl or is on dialysis.\n\nEC11. Subject has a history of bleeding diathesis or coagulopathy.\n\nEC12. Subject has Hgb \\\u003C9 g\u002FdL, platelet count \\\u003C50,000 cells\u002Fmm3 or \\>700,000 cells\u002Fmm3, or white blood cell count \\\u003C1,000 cells\u002Fmm3.\n\nEC13. Subject has had or plans to have an unrelated major surgical or interventional procedure (including trans-aortic interventions) within 30 days prior or post implantation of the device.\n\nEC14. Subject has known hypersensitivity to contrast agents that cannot be adequately pre-medicated or has known hypersensitivity to the device components.\n\nEC15. Subject is participating in another investigational drug or device study and has not completed the follow-up required for that study at least 30 days prior to signing the informed consent form in this study.\n\nEC16. Subject is morbidly obese (body mass index ≥ 40 kg\u002Fm2) or has other documented conditions that inhibit radiographic visualization of the aorta.\n\nEC17. Subject has an active infection or chronic systemic illness at the time of the index procedure that may interfere with study objectives.\n\nEC18. Subject has current problems with substance abuse.Smoking is NOT an exclusion criterion.\n\nEC19. Subject has severe incapacitating dementia.\n\nEC20. Subject has a life expectancy of less than 24 months due to comorbid conditions based on the assessment of the investigator at the time of enrollment.",{"count":283,"type":23},12,[133],"This clinical trial evaluates the safety and feasibility of the A3-Shield implant for stabilising small abdominal aortic aneurysms in adult patients. The study enrolls men and women with small, asymptomatic infrarenal abdominal aortic aneurysms who are eligible for an elective catheter-based procedure.\n\nThe trial aims to determine whether implantation of the A3-Shield device is technically feasible and whether it is associated with mechanical immobilization of the aneurysm neck. The study also assesses the peri-procedural and safety profile of the device.\n\nParticipants will undergo implantation of the A3-Shield device and attend scheduled follow-up visits that include clinical assessments and imaging such as ultrasound and computed tomography. The study does not include randomisation or a separate control group.",[287],"Aneurysm, Abdominal Aortic",[289,290,291],"A3-Shield","Small AAA","Pulse Wave Modulation",{"date":293,"type":47},"2026-01-09",{"date":295,"type":47},"2025-11-28",{"date":297,"type":23},"2028-07",{"name":299,"class":84},"Angiolutions GmbH",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":68,"phases":310,"briefSummary":311,"conditions":312,"keywords":315,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":55},"100563135","biliary-fistulas-in-surgery-of-liver-echinococcosis-100563135","NCT06612229","Biliary Fistulas in Surgery of Liver Echinococcosis","Improvement of Methodological Approaches to Diagnostics and Tactics of Treatment of Biliary Fistulas in Surgery of Liver Echinococcosis","BFISOLE","Inclusion Criteria:\n\n* Age under 18 years;\n* Informed consent for inclusion in the study;\n* The presence of liver echinococcosis, for which conservative surgical treatment will be performed;\n* The presence of the entire spectrum of necessary preoperative diagnostic measures;\n* A full description of all stages of surgical intervention, indicating the type of intervention (open or laparoscopic surgery, location and size of the echinococcal cyst in the liver, type of antiparasitic treatment, presence or absence of a biliary fistula in the residual cavity, actions taken in relation to the fistula, the option of eliminating the residual cavity and drainage;\n* Availability of objective data on the characteristics of the postoperative course, including dynamic indicators of the patient\\'s condition, temperature, amount and nature of discharge through the drainage, the time of drainage removal, the type of complications (if any) and the method of their treatment, the duration of the hospital period, data on the characteristics of the posthospital period up to 3 months of observation;\n* Absence of concomitant pathology that may affect the outcome of the surgery.\n\nExclusion Criteria:\n\n* Age under 18 years;\n* Refusal to participate in the study;\n* Extrahepatic echinococcosis without liver damage;\n* Absence of the full range of preoperative diagnostic data;\n* Difficulties with objective analysis of the features of the performed surgical treatment;\n* Incomplete data on monitoring the postoperative hospital and remote (up to 3 months) period;\n* The presence of concomitant pathology that may affect the outcome of the operation.",{"count":309,"type":23},200,[133],"The objective of the study is to improving the results of surgical treatment of liver echinococcosis complicated by biliary fistula by optimizing diagnostic approaches to early verification of this complication and improving the tactical and technical aspects of its elimination.",[313,314],"Echinococcosis, Hepatic","Biliary Fistula",[316,317,318],"Echinococcosis of the liver","Biliary fistula","Conservative surgical treatment","2025-12-29",{"date":321,"type":47},"2025-12-30",{"date":323,"type":47},"2023-10-22",{"date":325,"type":23},"2026-12-23",{"name":327,"class":54},"Republican Specialized Scientific and Practical Medical Center of Surgery Named After V. Vakhidov",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":344,"locationsCount":55},"100540385","presentation-of-protoscolexes-and-acephalocysts-in-the-fibrous-capsule-area-of-the-liver-with-echinococcosis-100540385","NCT06316154","Presentation of Protoscolexes and Acephalocysts in the Fibrous Capsule Area of the Liver With Echinococcosis","Presentation of Protoscolexes and Acephalocysts in the Fibrous Capsule Area of the Liver With Echinococcosis During Organ-preserving Surgery","PAFCLE","Inclusion Criteria:\n\n* Presence of primary or recurrent liver echinococcosis disease requiring surgical treatment\n* Cyst diametr \\>5 cm;\n* Performing one of the surgical treatment of liver echinococcosis with intraoperative sampling of part of the fibrous capsule with or without adjacent liver tissue for research;\n* Signed informed consent of patients for inclusion in the study;\n\nExclusion Criteria:\n\n* Liver echinococcosis with cysts less than 5 cm in diametr;\n* Presence of severe concomitant disorders","80 Years",{"count":228,"type":23},"The objective of the study is to determine the presence of germinal elements of echinococcosis in the liver parenchyma next to and in the thickness of the fibrous capsule of hydatid cysts.",[313],{"date":321,"type":47},{"date":323,"type":47},{"date":343,"type":23},"2026-12-25",{"name":327,"class":54},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":196,"enrollmentInfo":353,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":55},"100529116","verification-of-risk-factors-of-thrombohemorrhagic-complications-in-recipients-after-related-liver-transplantation-100529116","NCT06169592","Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation","Verification of Prognostic Risk Factors of Thrombohemorrhagic Complications in Early Follow-up Period in Recipients After Living Related Liver Transplantation","VORTAL","Inclusion Criteria:\n\n* Age over 18 years and up to 70 years;\n* Signed informed consent for inclusion to the study;\n* End stage liver cirrhosis.\n\nExclusion Criteria:\n\n* Pregnancy;\n* Extrahepatic factors influencing systemic hemostasis;\n* Concomitant hematological diseases affecting the hemostatic system;\n* Severe concomitant disorders.",{"count":354,"type":23},30,"The aim of the study is to improve the results of related transplantation of the right liver lobe by verifying the general predictors of the development of hemostatic system disorders and optimizing a comprehensive program for thrombohemorrhagic complications preventing.",[357,358],"Liver Cirrhosis","Liver Transplant; Complications",{"date":321,"type":47},{"date":361,"type":47},"2022-04-22",{"date":363,"type":23},"2026-12-16",{"name":327,"class":54},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":372,"enrollmentInfo":373,"targetDuration":4,"studyType":68,"phases":375,"briefSummary":376,"conditions":377,"keywords":381,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":55},"100611538","sakurabead-used-as-resorbable-embolic-for-plantar-fascia-embolization-100611538","NCT07241884","SakuraBead Used as Resorbable Embolic for Plantar Fascia Embolization","SURE-PF","Inclusion Criteria:\n\n1. Patient is able and willing to provide written informed consent, and\n2. Age 18 to 75 years (inclusive), and\n3. Clinical diagnosis of PF with proximal plantar fascia thickness greater than 4mm and areas of hypoechogenicity.\n\nExclusion Criteria:\n\n1. Acute internal derangement of the foot including acute meniscal, ligament or bone injury, or\n2. Sensory or motor neuropathy of the feet, or\n3. Heel pain caused by stress fractures, nerve entrapment, or inflammatory conditions such as arthritis, gout, or bursitis, or\n4. Prior surgical repair or plantar fascia rupture in the involved foot, or\n5. Local infection in either foot, or\n6. Contraindication to MRI, or\n7. Active pregnancy as demonstrated by urine or serum β-hCG or lactating female\n8. Unable to provide informed consent or comply with the conditions of the study, or\n9. At the discretion of the Principal Investigator","75 Years",{"count":374,"type":23},45,[133],"This is a prospective, single center, double arm, randomized, unmasked, First in Human study that aims to evaluate the safety and effectiveness of SakuraBead™ resorbable embolization microspheres in adult patients suffering from pain secondary to plantar fasciitis.",[378,379,380],"Plantar Fascitis","Heel Pain","Musculoskeletal Diseases",[382,383,384,379],"Fasciitis","Musculoskeletal disease","Foot disease","2025-11-17",{"date":387,"type":47},"2025-11-21",{"date":389,"type":47},"2025-10-20",{"date":391,"type":23},"2027-03",{"name":393,"class":84},"CrannMed",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":68,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":415},"100523700","safety-and-performance-of-endomatic-sepiola-left-atrial-appendage-laa-closure-device-100523700","NCT06099106","Safety and Performance of ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device","Evaluation of the Safety and Performance of ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation","Inclusion Criteria:\n\n* calculated CHA2DS2-VASc score of 2 or greater.\n* The subject is non-eligible or have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulants.\n* documented non-valvular atrial fibrillation\n* Subject suitable for vascular\u002Fcardiac intervention procedure\n* suitable LAA anatomical measurements for study device\n\nExclusion Criteria:\n\n* Subject who requires anticoagulation for a condition other than AF.\n* NYHA classification IV.\n* Complex congenital heart disease.\n* Presence of circumflex coronary artery stent.\n* The subject has a prosthetic valve in any position.\n* atrial septal defect closure or has an ASD\u002FPFO device.\n* presence of intracardiac thrombus.\n* Any cardiac surgery in the past\n* LVEF \\\u003C 35%.\n* intracardiac thrombus\n* moderate or severe mitral valve stenosis",{"count":273,"type":23},[133],"The study is designed to evaluate the safety and performance of the ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device in Patients with non-valvular Atrial Fibrillation, who are at increased risk for stroke, and that cannot take, or have a reason to seek an alternative, to long-term anticoagulation therapy.\n\nPotential patients who are candidates for LAA closure will be screened to confirm that all inclusion\u002Fexclusion criteria are met, with final eligibility confirmation on day of procedure.\n\nAll enrolled subjects who went through the procedure will be followed during the procedure to hospital discharge.\n\nAdditional follow up time points are scheduled at 45 days, 6 months and 12 months post procedure.",[405],"Atrial Fibrillation","2025-08-13",{"date":408,"type":47},"2025-08-17",{"date":410,"type":47},"2023-05-01",{"date":412,"type":23},"2027-05",{"name":414,"class":84},"Endomatic Ltd.",5,{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":17,"sex":63,"minAge":422,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":426,"conditions":427,"keywords":429,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":283},"100294654","the-k-map-study-global-prevalence-of-kc-100294654","NCT03115710","The K-Map Study, Global Prevalence of KC","Inclusion Criteria:\n\n* Male or female, 6-23 years of age.\n* Subjects seen for a non-ophthalmic appointment\n* Provide signed and dated patient consent form (signed by parents \u002F legal guardians).\n* Willing to comply with all study procedures and be available for the duration of the study\n\nExclusion Criteria:\n\n* Patients with a preexisting ocular disease \u002F condition\n* Pregnancy or breastfeeding","6 Years","23 Years",{"count":425,"type":23},20000,"Keratoconus is a ocular disease classified under ectatic diseases which often results in bilateral and asymmetrical corneal distortion. It usually affects patients at young age and can cause severe visual loss.\n\nThe overall goal of this study is to assess the prevalence of keratoconus (KC) in children and adolescents in various regions of the world based on modern tomographic imaging methods, and to verify whether the occurrence rates reported from literature should be corrected. Our hypothesis is that the prevalence of the disease is much higher than that traditionally reported.\n\nAt each site, corneal tomography examinations (Pentacam) will be performed bilaterally in children and adolescents, who are not ill or with any ophthalmological symptom. The population to be studied will be composed of children and adolescents on medical visits for non-ophthalmologic reasons, aged between 6 and 20 years. Multiple cities, from different continents (North America, South America, Asia and Europe) will participate.",[428],"Keratoconus",[428,430],"Prevalence","2025-08-06",{"date":433,"type":47},"2025-08-11",{"date":435,"type":47},"2015-12-28",{"date":437,"type":23},"2030-02-01",{"name":439,"class":54},"University Hospital, Geneva",{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":63,"minAge":447,"maxAge":422,"enrollmentInfo":448,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":450,"conditions":451,"keywords":453,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":465},"100598057","trial-of-the-efficacy-and-safety-of-use-of-drug-product-reamberin-for-pathogenetic-therapy-of-viral-enteric-infection-in-children-aged-1-6-years-old-100598057","NCT07066540","Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old","Open Multicenter Prospective Observational Trial of the Efficacy and Safety of Use of Drug Product Reamberin® Solution for Infusion, 1.5 % (Scientific Technological Pharmaceutical Firm \"POLYSAN\") for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old","Inclusion Criteria:\n\n1. Children of both sexes at the age of 1 to 6 years old inclusive;\n2. Diagnosis \"Viral and other specified intestinal infections\" (code according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision(ICD-10): A08),\n3. Clinical signs of endogenous intoxication (nausea, vomiting, hyperthermia, headache, muscle pain, asthenia, adynamia, etc.);\n4. Indication for parenteral rehydratation (infusion therapy);\n5. Decision of a physician on prescribing drug product Reamberin® solution for infusion, 1.5 % (Scientific Technological Pharmaceutical Firm \"POLYSAN\") in the daily dose of 10 mL\u002Fkg and normal saline NaCl\u002F5 % or 10 % solution of glucose or normal saline NaCl\u002FRinger's solution\u002F5 % or 10 % solution of glucose;\n6. To confirm the diagnosis by laboratory tests, biological material was taken;\n7. Informed Consent Form on Participation in the Observational Program signed and dated by a parent\u002Flegal representative of the patient.\n\nExclusion Criteria:\n\n1. Individual intolerance or known hypersensitivity to sodium meglumine, sodium succinate, and\u002For normal saline (NaCl), solution of glucose, Ringer's solution or excipients of drug product Reamberin® based on data of medical history;\n2. Contraindications to prescription of drug product Reamberin®;\n3. Necessity in surgical interventions during the observational program;\n4. Patients previously enrolled in this trial but discontinued participation due to any any reason;\n5. Administration of antibiotics or succinate-containing drug products (Cytoflavin, Mexidol, etc.) and solutions containing malate;\n6. Other conditions that, according to the Investigator, prevent enrollment of a patient into the observational trial or can result in premature discontinuation of the observational trial by the patient","1 Year",{"count":449,"type":23},300,"To assess the efficacy and safety of use of drug product Reamberin® solution for infusion, 1.5 % (Scientific Technological Pharmaceutical Firm \"POLYSAN\") for pathogenetic therapy of viral enteric infection in children aged 1-6 years old in routine clinical practice. Trial population: children of both sexes at the age of 1-6 years old inclusive with viral enteric infection.",[452],"Viral Enteric Infection",[454,455],"viral enteric infection","reamberin","2025-07-12",{"date":458,"type":47},"2025-07-15",{"date":460,"type":47},"2024-08-01",{"date":462,"type":23},"2026-12",{"name":464,"class":84},"POLYSAN Scientific & Technological Pharmaceutical Company",8,{"id":467,"slug":468,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":68,"phases":475,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":494},"100568008","extensive-multilayer-stent-treatment-in-aortic-dissection-100568008","NCT06675617","EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn","A Clinical Study to Evaluate the Effectiveness and Safety of the Allay® Aortic Stent as Adjunctive Endovascular Treatment of Type B Aortic Dissection in Patients Eligible for Thoracic Endovascular Repair With Stent Grafts","EXTENSO","Inclusion Criteria:\n\n* Have a type B aortic dissection extending to the celiac trunk or beyond\n* Are eligible for thoracic endovascular treatment with stent grafts as per local guidelines, and physician's decision\n* Have been elected for treatment with commercially available stent graft as per their IFU within 90 days of dissection symptoms onset\n\nExclusion Criteria:\n\n* General Exclusion Criteria:\n\n  * Age \\\u003C 18 years\n  * Pregnant, breast-feeding or planning on becoming pregnant during the entire duration of the study\n  * Unable to provide written informed consent\n  * Unable or unwilling to comply with the requirements of the study protocol\n  * Taking part already in an investigational device or drug study that could interfere with the outcomes being studied\n  * Active drug addiction or known history of drug abuse within one year of treatment\n* Medical Exclusion Criteria:\n\n  * Aortic rupture, free or contained including haemothorax, increasing periaortic hematoma, or mediastinal hematoma\n  * Aortic fistula\n  * Suspicion of bowel necrosis or irreversible visceral ischemia\n  * Stage 5 chronic kidney disease\n  * Life expectancy of less than 2 years due to any other medical condition than the dissection to be treated\n  * Active malignancy\n  * Known sensitivities or allergies to the device materials (including cobalt, chromium, nickel)\n  * Known sensitivities or allergies to contrast materials that cannot be pre-medicated\n  * Mycotic aortic aneurysm or active systemic infection that may place the patient at increased risk of endovascular infection\n  * American Society of Anaesthesiologists (ASA) class V (moribund patient not expected to live 24 hours with or without operation)\n  * Diagnosed or suspected congenital degenerative connective tissue disease (e.g., Marfan's, Loeys-Dietz or Ehlers-Danlos syndrome)\n  * Uncorrectable coagulopathy, bleeding diathesis or refusal of blood transfusion\n  * Any major cardiovascular or cerebrovascular ischemic event, including myocardial infarction or stroke, or treatment of such event, within 90 days prior to enrolment\n  * Any aortic-related interventional or surgical procedure within 30 days prior to enrolment\n  * Any planned aortic-related interventional or surgical procedure within 30 days after the study procedure\n* Anatomical Exclusion Criteria:\n\n  * Aneurysmal dilatation of the false lumen defined as maximum transaortic diameter \\>55 mm in women or \\>60 mm in men in the thoraco-abdominal segment or \\>50 mm in women or \\>55 mm in men in the abdominal segment, measured inner-wall to inner-wall;\n  * Inadequate proximal landing zone for the stent graft, such zone being \\\u003C20 mm long\n  * Inadequate proximal landing zone geometry for the Allay® Aortic Stent (e.g. aortic kink)\n  * Planned implantation of a stent graft with a distal diameter \\>38 mm or \\\u003C20 mm\n  * Aorta or iliac anatomy not allowing the advancement of the delivery system\n  * Subject in whom the thoracic stent graft is either 1) not implanted in its intended position and\u002For 2) leads to any serious device complication, and\u002For who has 3) persistent static obstruction of the visceral or both renal arteries, prior to Allay® Aortic Stent implantation, will not be implanted with the Allay® Aortic Stent and will be withdrawn from the study",{"count":131,"type":23},[133],"This clinical trial is a prospective, multicenter, open label study designed to evaluate the effectiveness and the safety of the Allay® Aortic Stent as adjunctive endovascular treatment of Type B aortic dissection in patients eligible for thoracic endovascular aortic repair with stent grafts.",[478],"Type B Aortic Dissection",[480,481,482,483,484],"TBAD","Allay","aortic","dissection","type B","2025-05-16",{"date":487,"type":47},"2025-05-18",{"date":489,"type":47},"2024-10-30",{"date":491,"type":23},"2031-06",{"name":493,"class":84},"Intressa Vascular SA",10,{"id":496,"slug":497,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":11,"sex":63,"minAge":502,"maxAge":503,"enrollmentInfo":504,"targetDuration":4,"studyType":68,"phases":506,"briefSummary":508,"conditions":509,"keywords":512,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":55},"100536671","early-phase-1-development-of-methods-for-effective-treatment-and-improvement-of-common-somatic-diseases-in-children-100536671","NCT06267859","Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children","Based on Medical Statistical Analysis and Screening (Dispensary) Examination, Identification of the Most Common Somatic and Congenital Diseases in Children, With the Further Development of More Effective Methods of Treatment and Recovery","Inclusion Criteria:\n\n* children from birth to 15 years;\n* children permanently residing in the territory where the clinical examination is carried out;\n* children included in the group of \"frequently ill children\";\n* patients without severe chronic diseases.\n\nExclusion Criteria:\n\n* Teenagers over 15 years old;\n* Patients with severe neurological and mental diseases;\n* Patients with endocrinological diseases;\n* Patients with long-term chronic somatic diseases;\n* Children without genetic pathologies.","3 Days","15 Years",{"count":505,"type":23},110,[507],"EARLY_PHASE1","The goal of the clinical study is to clarify the course of common congenital, infectious, and non-infectious diseases in children living in Uzbekistan, and to develop methods for their treatment and rehabilitation.\n\nThe main questions it aims to answer:\n\n* Analysis of common congenital diseases among children;\n* Analysis of commonly diagnosed bronchopulmonary and cardiovascular diseases among children;\n* Based on the results of the primary research, common diseases among children will be identified;\n* Analysis of existing treatment methods and their effectiveness;\n* Development of modern methods of treatment and rehabilitation of children.",[510,511],"Respiratory Diseases","Congenital Heart Defects",[513,514,515,516,517],"children","adolescents","heart diseases","lung diseases","congenital malformations",{"date":519,"type":47},"2025-05-21",{"date":521,"type":47},"2023-11-08",{"date":523,"type":23},"2034-01-30",{"name":525,"class":54},"Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan",{"id":527,"slug":528,"hasResults":11,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":533,"enrollmentInfo":534,"targetDuration":4,"studyType":68,"phases":536,"briefSummary":537,"conditions":538,"keywords":540,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":555},"100590718","vacuum-assisted-laser-ablation-vala-for-treatment-of-large-saphenous-veins-100590718","NCT06971068","Vacuum-assisted Laser Ablation (VALA) for Treatment of Large Saphenous Veins","Endovenous Vacuum-assisted Laser Ablation (VALA) in the Treatment of Large Saphenous Veins (> 15 mm)","Inclusion Criteria:\n\n* Age over 18 years\n* Varicose veins of the lower extremities with clinical class C2-C6 with a diameter of the GSV or SSV ≥ 15 mm in a standing position\n* Informed consent\n\nExclusion Criteria:\n\n* pregnancy or lactation\n* malignant neoplasms\n* inability or unwillingness of any patient to wear compression stockings\n* hypersensitivity to lidocaine\n* concomitant diseases: diabetes mellitus, bronchial asthma, severe liver and kidney diseases, acute thrombosis and thrombophlebitis, skin and\u002For soft tissue infection, infectious diseases, obliterating peripheral arteriosclerosis, diabetic angiopathy, heart defects requiring surgical intervention, fever, toxic hyperthyroidism, obesity, tuberculosis, sepsis, blood cell composition disorder, all diseases requiring bed rest, heart disease with decompensation, known hereditary thrombophilia\n* period after treatment for alcohol addiction\n* sedentary lifestyle\n* history of acute deep vein thrombosis\n* history of superficial thrombophlebitis\n* history of drug or other addiction\n* use of oral contraceptives or other hormonal drugs","90 Years",{"count":535,"type":23},184,[133],"Endovenous thermal ablation (EVTA), including radiofrequency ablation (RFA) and endovenous laser ablation (EVLA), is considered the main method for the treatment of symptomatic truncal vein reflux. However, there are controversial data concerning their efficacy and safety in ablating large saphenous veins because of high risk of heat-induced thrombosis (EHIT), incomplete ablation and recanalization.1-5 The use of vacuum evacuation of the remaining intraluminal blood during endovenous laser ablation allows to decrease the risk of intraoperative (carbonization and destruction of the fiber lens) and postoperative complications (EHIT, hyperpigmentation, \"string\" feeling) and leads to reduction of recovery because of short period of vein resorption. The aim of the study is to evaluate the safety and effectiveness of endovenous thermal ablation with or without vacuum evacuation for the treatment of incompetent large saphenous veins (\\>15 mm).",[539],"Varicose Veins",[541,542,543,544],"Vacuum-assisted Laser Ablation","large saphenous veins","varicose veins","EVLA","2025-05-10",{"date":547,"type":47},"2025-05-14",{"date":549,"type":47},"2025-03-15",{"date":551,"type":23},"2026-02-15",{"name":553,"class":554},"Center Of Phlebology","NETWORK",9,{"id":557,"slug":558,"hasResults":11,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":11,"sex":63,"minAge":4,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":564,"conditions":565,"keywords":567,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":55},"100408526","unstable-angina-pectoris-in-comorbidity-with-anxiety-depressive-syndrome-100408526","NCT04599621","Unstable Angina Pectoris in Comorbidity With Anxiety-depressive Syndrome","Immunological Features of Unstable Angina Pectoris in Comorbidity With Anxiety-depressive Syndrome","Inclusion Criteria:\n\n* the presence of an established diagnosis in patients with coronary artery disease\n* unstable angina pectoris (NS). When making a diagnosis, the recommendations of ESH \u002F ESC (2015) and RCO \u002F WHO (2014) were used.\n* stable exertional angina (SSN) I-III FC. When making the diagnosis, the IHD classification was used, adopted at the IV Congress of Cardiologists of the Republic of Uzbekistan (2000), as well as in accordance with the recommendations of ESH \u002F ESC (2019) and RCO \u002F WHO (2017)\n\nExclusion Criteria:\n\n* The patient's refusal to participate in the study;\n* Pregnancy and lactation;\n* Severe and unstable condition of the patient, making it difficult to conduct a questionnaire (for ethical reasons);\n* Acute violation of cerebral circulation;\n* History of acute or chronic psychosis;\n* The presence of concomitant acute diseases or chronic diseases in the acute stage.\n\nThroughout the study, all patients were assigned the right to voluntarily withdraw from the study at their own request, notifying the researcher in writing or orally.",{"count":121,"type":23},"Introduction:\n\nToday it is necessary to emphasize that coronary heart disease is often associated with anxiety disorders. Research over the years has shown several and sometimes surprising links between coronary heart disease and mental illness, and has even suggested that both of these phenomena may actually cause each other. However, the exact nature of these links has not yet been clearly established.\n\nMethods: The study included 202 patients with coronary artery disease, of whom 42 patients were with stable angina pectoris, they participated as a control group, and 160 patients with unstable angina pectoris, who made up the main group.\n\nAmong them there are 102 women and 100 men between the ages of 30 and 88. The average age was 63.75 ± 11.37 years.\n\nAll study participants had blood in the morning on fasting after 8-12 hours of fasting from the cubital vein. Determination of the level of cytokines TNF-α, IL-1β, IL-4 and IL-10 in blood serum by enzyme-linked immunosorbent assay (ELISA).\n\nAll participants in the study had blood drawn in the morning on fasting after 8-12 hours of fasting from the cubital vein. The level of uric acid was determined on the CYAN Start apparatus using a unified method.\n\nWhen examining patients with unstable angina pectoris were used: hospital anxiety and depression scale \\[Kozlova S.N. 2013\\]. And also the Spielberger-Khanin scale \\[Psychiatry - Hoffman A.G. 2010\\], developed by Spielberger Ch.D. and adapted by Yu.L. Khanin. to assess cognitive functions \\[Psychiatry - Gofman A.G. 2010\\].",[566],"Coronary Heart Disease",[568,569,570],"unstable angina pectoris","uric acid","cytokine imbalance","2020-10-16",{"date":573,"type":47},"2020-10-23",{"date":575,"type":47},"2018-11-05",{"date":577,"type":23},"2027-12-28",{"name":579,"class":54},"Samarkand State Medical Institute",""]